




ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gen G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Donald C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Lawrence B. Bugaisky
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackmany
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier

Rae Lynn P. Guest
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchet
Timothy A. Doyle*
Gaby L. Longsworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer

Laura A. Vogel
Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn*
Matthew E. Kelley*
Shannon A. Carroll*
Nicole R. Kramer*

Michelle K. Holoubek
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland

*Admitted only in Virginia

*Practice Limited to

Federal Agencies

January 5, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8805

INTERNET ADDRESS:
VRUTHERF@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1642

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/825,688; Filed: April 16, 2004
For: **Method of Identifying Compounds That Specifically Inhibit the Anaphase Promoting Complex**
Inventors: VODERMAIER *et al.*
Our Ref: 0652.2610001/EKS/VSR

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Information Disclosure Statement By Applicant (PTO/SB/08A), 1 page citing 3 documents (FP1-FP3);
3. Information Disclosure Statement By Applicant (PTO/SB/08B), 4 pages citing 36 documents (NPL1-NPL10, NP11-NPL20, NPL21-NPL30 and NPL31-NPL36);
4. Copies of FP1-FP3, NPL1-NPL10, NP11-NPL20, NPL21-NPL30 and NPL31-NPL36; and
5. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
January 5, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Victoria S. Rutherford
Agent for Applicants
Registration No. 52,253

VSR:amr
Enclosures

479068_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VODERMAIER *et al.*

Appl. No.: 10/825,688

Filed: April 16, 2004

For: **Method of Identifying Compounds
That Specifically Inhibit the
Anaphase Promoting Complex**

Confirmation No.: 8679

Art Unit: 1642

Examiner: *To Be Assigned*

Atty. Docket: 0652.2610001/EKS/VSR

**Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the documents are submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Victoria S. Rutherford
Victoria S. Rutherford
Agent for Applicants
Registration No. 52,253

Date: Jan 4, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

456326_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

(Use as many sheets as necessary)

Sheet

1

1

Complete if Known

Application Number	10/825,688
Filing Date	April 16, 2004
First Named Inventor	Hartmut VODERMAIER
Art Unit	1642
Examiner Name	<i>To Be Assigned</i>
Attorney Docket Number	0652.2610001/EKS/VSR

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	WO 96/33286 A1	10/24/1996	President and Fellows of Harvard College		
	FP2	WO 98/21326 A1	05/22/1998	Boehringer Ingelheim International GmbH and Nasmyth <i>et al.</i>		
	FP3	WO 02/00923 A1	01/03/2002	Boehringer Ingelheim International GmbH and Gmachl <i>et al.</i>		

456334 1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/825,688
				Filing Date	April 16, 2004
				First Named Inventor	Hartmut VODERMAIER
				Art Unit	1642
				Examiner Name	<i>To Be Assigned</i>
Sheet	1	of	4	Attorney Docket Number	0652.2610001/EKS/VSR

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		T ²
	NPL1	Au, S. W., <i>et al.</i> , "Implications for the Ubiquitination Reaction of the Anaphase-promoting Complex from the Crystal Structure of the Doc1/Apc10 Subunit," <i>J. Mol. Biol.</i> 316:955-968, Elsevier Science Ltd. (March 2002)		
	NPL2	Blatch, G. L. and Lassle, M., "The tetratricopeptide repeat: a structural motif mediating protein-protein interactions," <i>Bioessays</i> 21:932-939, John Wiley & sons, Inc. (1999)		
	NPL3	Carroll, C. W. and Morgan, D. O., "The Doc1 subunit is a processivity factor for the anaphase-promoting complex," <i>Nat. Cell. Biol.</i> 4:880-887, Nature Publishing Group (November 2002)		
	NPL4	Gatto, G. J., Jr., <i>et. al.</i> , "Peroxisomal targeting signal-1 recognition by the TPR domains of human PEX5," <i>Nat. Struct. Biol.</i> 7:1091-1095, Nature America, Inc. (2000)		
	NPL5	Gershkovich, A.A. and Kholodovych, V.V, "Fluorogenic substrates for proteases based on intramolecular fluorescence energy transfer (IFETS)," <i>J. Biochem. Biophys. Meth.</i> 33:135-162, Elsevier Science B.V. (1996)		
	NPL6	Gieffers, C., <i>et al.</i> , "Three-Dimensional Structure of the Anaphase-Promoting Complex," <i>Mol. Cell.</i> 7:907-913, Cell Press (2001)		
	NPL7	Gieffers, C., <i>et al.</i> , "Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons," <i>Proc. Natl. Acad. Sci. USA</i> 96:11317-11322, The National Academy of Sciences (1999)		
	NPL8	Gmachl, M., <i>et al.</i> , "The RING-H2 finger protein APC11 and the E2 enzyme UBC4 are sufficient to ubiquitinate substrates of the anaphase-promoting complex," <i>Proc. Natl. Acad. Sci. USA</i> 97:8973-8978, The National Academy of Sciences (2000)		
	NPL9	Grossberger, R., <i>et al.</i> , "Characterization of the DOC1/APC10 Subunit of the Yeast and the Human Anaphase-promoting Complex," <i>J. Biol. Chem.</i> 274:14500-14507, The American Society for Biochemistry and Molecular Biology, Inc. (1999)		
	NPL10	Harper, J. W., <i>et al.</i> , "The anaphase-promoting complex: it's not just for mitosis any more," <i>Genes Dev.</i> 16:2179-2206, Cold Spring Harbor Laboratory Press (September 2002)		
Examiner Signature			Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/825,688
				Filing Date	April 16, 2004
				First Named Inventor	Hartmut VODERMAIER
				Art Unit	1642
				Examiner Name	<i>To Be Assigned</i>
Sheet	2	of	4	Attorney Docket Number	0652.2610001/EKS/VSR

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		
	NPL11	Hatfield P.M., <i>et al.</i> , "Cloning of Ubiquitin Activating Enzyme from Wheat and Expression of a Functional Protein in <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 265:15813-15817, The American Society for Biochemistry and Molecular Biology, Inc. (1990)		T ²
	NPL12	Kieber-Emmons, T., <i>et al.</i> , "Therapeutic peptides and peptidomimetics," <i>Curr. Opin. Biotechnol.</i> 8:435-441, Current Biology Ltd. (1997)		
	NPL13	Kominami, K., <i>et al.</i> , "Apc10 and Ste9/Srw1, two regulators of the APC-cyclosome, as well as the CDK inhibitor Rum1 are required for G ₁ cell-cycle arrest in fission yeast," <i>EMBO J.</i> 17:5388-53 99, Oxford University Press (1998)		
	NPL14	Kramer, E. R., <i>et al.</i> , "Activation of the human anaphase-promoting complex by proteins of the CDC20/Fizzy family," <i>Curr. Biol.</i> 8:1207-1210, Current Biology Ltd. (1998)		
	NPL15	Kramer, E. R., <i>et al.</i> , "Mitotic Regulation of the APC Activator Proteins CDC20 and CDH1," <i>Mol. Biol. Cell.</i> 11:1555-1569, The American Society for Cell Biology (2000)		
	NPL16	Lamb, J. R., <i>et al.</i> , "Cdc16p, Cdc23p and Cdc27p form a complex essential for mitosis," <i>EMBO J.</i> 13:4321-4328, Oxford University Press (1994)		
	NPL17	Leverson, J. D., <i>et al.</i> , "The APC11 RING-H2 Finger Mediates E2-Dependent Ubiquitination," <i>Mol. Biol. Cell.</i> 11:2315-2325, The American Society for Cell Biology (2000)		
	NPL8	Matayoshi, E.D., <i>et al.</i> , "Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer," <i>Science</i> 247:954-958, American Association for the Advancement of Science (1990)		
	NPL19	Murray, A.W., "Cell Cycle Extracts," in <i>Methods in Cellular Biology</i> , Kay, B.K. and Peng, H.B., eds., Academic Press, Inc., San Diego, CA, pp. 581-605 (1991)		
	NPL20	Ohta, T., <i>et al.</i> , "ROC1, a Homolog of APC11, Represents a Family of Cullin Partners with an Associated Ubiquitin Ligase Activity," <i>Mol. Cell.</i> 3:535-541, Cell Press (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/825,688
Sheet	3	of	4	Filing Date	April 16, 2004
				First Named Inventor	Hartmut VODERMAIER
				Art Unit	1642
				Examiner Name	To Be Assigned
				Attorney Docket Number	0652.2610001/EKS/VSR

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published			T ²
	NPL21	Passmore, L. A., <i>et al.</i> , "Doc1 mediates the activity of the anaphase-promoting complex by contributing to substrate recognition," <i>EMBO J.</i> 22:786-796, Oxford University Press (February 2003)			
	NPL22	Peters, J.-M., "The Anaphase-Promoting Complex: Proteolysis in Mitosis and Beyond," <i>Mol. Cell.</i> 9:931-943, Cell Press (May 2002)			
	NPL23	Pickart, C. M., "Mechanisms Underlying Ubiquitination," <i>Annu. Rev. Biochem.</i> 70:503-533, Annual Reviews (2001)			
	NPL24	Ripka A.S. and Rich D.H., "Peptidomimetic design," <i>Curr. Opin. Chem. Biol.</i> 2:441-452, Current Biology Publications (1998)			
	NPL25	Schwab, M., <i>et al.</i> , "Yeast Hct1 recognizes the mitotic cyclin Clb2 and other substrates of the ubiquitin ligase APC," <i>EMBO J.</i> 20:5165-5175, Oxford University Press (2001)			
	NPL26	Tang, Z., <i>et al.</i> , "APC2 Cullin Protein and APC11 RING Protein Comprise the Minimal Ubiquitin Ligase Module of the Anaphase-promoting Complex," <i>Mol. Biol. Cell.</i> 12:3839-3851, The American Society for Cell Biology (2001)			
	NPL27	Vodermaier, H. C., "Cell cycle: Waiters serving the Destruction machinery," <i>Curr. Biol.</i> 11:R834-R837, Elsevier Science Ltd. (2001)			
	NPL28	Wendt, K. S., <i>et al.</i> , "Crystal structure of the APC10/DOC1 subunit of the human anaphase-promoting complex," <i>Nat. Struct. Biol.</i> 8:784-788, Nature America, Inc. (2001)			
	NPL29	Yu, H., <i>et al.</i> , "Identification of a Cullin Homology Region in a Subunit of the Anaphase-Promoting Complex," <i>Science</i> 279:1219-1222, American Association for the Advancement of Science (1998)			
	NPL30	Zachariae, W., <i>et al.</i> , "Control of Cyclin Ubiquitination by CDK-Regulated Binding of Hct1 to the Anaphase Promoting Complex," <i>Science</i> 282:1721-1724, American Association for the Advancement of Science (1998)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/825,688
				Filing Date	April 16, 2004
				First Named Inventor	Hartmut VODERMAIER
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	4	of	4	Attorney Docket Number	0652.2610001/EKS/VSR

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		T ²
	NPL31	Zachariae, W., <i>et al.</i> , "Mass Spectrometric Analysis of the Anaphase-Promoting Complex from Yeast: Identification of a Subunit Related to Cullins," <i>Science</i> 279:1216-1219, American Association for the Advancement of Science (1998)		
	NPL32	Zheng, N., <i>et al.</i> , "Structure of the Cull1-Rbx1-Skp1-F box ^{Skp2} SCF ubiquitin ligase complex," <i>Nature</i> 416:703-709, Nature Publishing Group (April 2002)		
	NPL33	NCBI Entrez, GenBank Report, Accession No. NP_001247, Zhou, Y., <i>et al.</i> , Entry Date 1999, Last Updated October 2005		
	NPL34	NCBI Entrez, GenBank Report, Accession No. NP_057322, Yu, H., <i>et al.</i> , Entry Date 2000, Last Updated September 2005		
	NPL35	NCBI Entrez, GenBank Report, Accession No. U39317, Jensen, J.P., <i>et al.</i> , Entry Date 1996, Last Updated 1996		
	NPL36	NCBI Entrez, GenBank Report, Accession No. M55604, Hatfield, P.M., <i>et al.</i> , Entry Date 1993, Last Updated 1994		

456331_1.DOC

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.